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Abstract
This study investigated the impact of chronic exposure to continuous (CoP4) versus cyclic progesterone (CyP4) alone or in
combination with 17b-estradiol (E2) on gene expression profiles targeting bioenergetics, metabolism and inflammation in
the adult female rat hippocampus. High-throughput qRT-PCR analyses revealed that ovarian hormonal depletion induced
by ovariectomy (OVX) led to multiple significant gene expression alterations, which were to a great extent reversed by co-
administration of E2 and CyP4. In contrast, co-administration of E2 and CoP4 induced a pattern highly resembling OVX.
Bioinformatics analyses further revealed clear disparities in functional profiles associated with E2+CoP4 and E2+CyP4. Genes
involved in mitochondrial energy (ATP synthase a subunit; Atp5a1), redox homeostasis (peroxiredoxin 5; Prdx5), insulin
signaling (insulin-like growth factor I; Igf1), and cholesterol trafficking (liver X receptor a subtype; Nr1h3), differed in
direction of regulation by E2+CoP4 (down-regulation relative to OVX) and E2+CyP4 (up-regulation relative to OVX). In
contrast, genes involved in amyloid metabolism (b-secretase; Bace1) differed only in degree of regulation, as both E2+CoP4
and E2+CyP4 induced down-regulation at different efficacy. E2+CyP4-induced changes could be associated with regulation
of progesterone receptor membrane component 1(Pgrmc1). In summary, results from this study provide evidence at the
molecular level that differing regimens of hormone therapy (HT) can induce disparate gene expression profiles in brain.
From a translational perspective, confirmation of these results in a model of natural menopause, would imply that the
common regimen of continuous combined HT may have adverse consequences whereas a cyclic combined regimen, which
is more physiological, could be an effective strategy to maintain neurological health and function throughout menopausal
aging.
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Introduction
Combinations of estrogens and progestogens in varying
regimens are used world-wide as hormone therapy (HT) for
menopause-related climacteric symptoms [1,2]. Despite the
widespread use of HT, the neurological impact of clinically
relevant chronically administered HT combinations and regimens
is less understood than associations with cancer and vascular
disease.
Preclinical and clinical data indicate that the composition of
HT, in particular the progestogen component, is a critical factor in
the impact of HT on cognition [3]. The largest clinical trial of HT
for neural outcomes, the Women’s Health Initiative Memory
Study (WHIMS), indicated an adverse effect of combined HT of
conjugated equine estrogens (CEE) and medroxyprogesterone
acetate (MPA) on neurological health when initiated in women
aged 65 years and older [4,5]. In contrast, neither benefit nor
detriment was observed among women treated with CEE alone
[6,7]. The different outcomes between CEE+MPA and CEE alone
trials suggest that the addition of the synthetic progestogen, MPA,
to the estrogen formulation exacerbated neurological decline in
some postmenopausal women 70 years or older. These clinical
findings are consistent with preclinical observations from animal
models demonstrating that MPA antagonized the positive effects
of 17b-estradiol (E2) on neuronal mitochondrial function and
survival and synaptic plasticity [2,8].
The principle endogenous progestogen, progesterone (P4), has
both direct effects on the female brain including the hippocampus
and cortex, and indirect effects through interactions with estrogen
[3]. Our preclinical studies indicated that synergistic versus
antagonistic interactions of P4 with E2 are sensitive to specific
treatment paradigms. In both in vitro and in vivo studies, the acute
simultaneous exposure to the combination of E2 and P4
antagonized the benefits of exposure to E2 alone [9,10]. In a
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E2 and P4 for 3 months, the b-amyloid (Ab)-reducing action of E2
was blocked by continuous exposure to P4 for 90 days, while cyclic
exposure to P4 for 3610 day periods significantly reduced Ab
levels when used alone and enhanced E2-induced Ab reduction
[11,12]. Conversely, in the hypothalamic regulation of ovarian
cycles, continuous P4 protected mice from hypothalamic desen-
sitization induced by continuous exposure to E2 [13]. Collectively,
these data suggest that continuous versus cyclic regimens of HT
have substantially divergent impact on brain outcomes critical to
optimal neural function and prevention of AD and other
neurodegenerative diseases. Another complexity is that rodent
reproductive cycles (4–5 days) and pregnancy (18–20 days) are
short relative to the duration of human HT (typically, 30–90 day
phases), which few studies have addressed at the level of gene
expression.
The present study determined, at the gene expression level, the
differential impact of continuous versus cyclic exposure to P4
alone or in combination of E2, on the hippocampus, a brain
region involved in cognition that is damaged in AD. Adult female
rats were ovariectomized (OVX) and given continuous E2
replacement with two P4 schedules, continuous P4 (CoP4) or
cyclic P4 (CyP4). The hippocampal expression of a focused group
of genes involved in pathways/processes including bioenergetics,
metabolism and inflammation that have been widely associated
with cognitive aging and AD [14,15,16,17], were profiled by qRT-
PCR. A bioinformatics analysis further determined gene networks,
signaling and metabolic pathways, as well as biological functions
and diseases that can be potentially perturbed by different
regimens. These analyses indicate profound differences between
continuous versus cyclic exposure to P4 on genomic and associated
functional regulation indicative of neurological heath or vulner-
ability to brain metabolic deficits.
Results
Seven intervention groups, Sham-OVX (treated with vehicle
only), OVX (treated with vehicle only), OVX treated with E2
alone (OVX+E2), OVX treated with continuous P4 (OVX+-
CoP4), OVX treated with cyclic P4 (OVX+CyP4), OVX treated
with E2 in combination with continuous P4 (OVX+E2+CoP4),
and OVX treated with E2 in combination with cyclic P4
(OVX+E2+CyP4), were included in the present study (Fig. 1A).
Endocrine responses to different hormone interventions and
treatment paradigms were confirmed by uterine weight (Fig. 1B).
Consistent with previous reports, when compared to Sham-OVX,
hormone deprivation induced by OVX led to an approximate
50% reduction in uterine weight (P,0.01). Uterine weight in E2
treatment groups including OVX+E2, OVX+E2+CoP4 and
OVX+E2+CyP4 did not differ from Sham-OVX. Uterine weight
in P4 alone treatment groups including OVX+CoP4 and
OVX+CyP4 did not differ from OVX (Fig. 1B).
Hippocampal gene expression in response to different hormone
interventions and treatment paradigms were comparatively
analyzed using qRT-PCR-based Taqman low-density arrays
(TLDAs). Selection of control genes for data normalization was
based upon the control stability measure (M). Among 4 candidate
control genes, Gapdh exhibited the most stable expression across
all samples, with the lowest M=0.52 (as compared to Actb
(M=0.54), Hprt1 (M=0.76) and 18 S (M=0.82)), and therefore
was used as the control gene in the following data analyses. Of the
163 target genes assayed, 24 genes (listed in grey in Table S1),
were undetermined for at least one of two reasons: 1) no
amplification possibly due to low expression or failed assays; 2)
two or fewer samples with undetectable Ct values within any of the
seven groups. A total of 139 genes (Ct values listed in Table S2)
were analyzed for their fold change in expression relative to the
OVX comparison group. Among them, 49 genes exhibited a fold
change with P,0.05 relative to OVX in at least one of the 6
treatment groups (Table S3).
CoP4 and CyP4 differentially regulate gene expression
profiles
Mitochondrial energy and redox metabolism. Of the 24
mitochondrial energy and redox metabolism related genes
Figure 1. Hormone interventions and treatment paradigms (A) and uterine responses (B). OVX: ovariectomy; E2: 17b-estradiol; CoP4:
continuous P4; CyP4: cyclic P4.
doi:10.1371/journal.pone.0031267.g001
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Polg, Ppargc1b, Prdx5,Sirt1,Slc25a4,Slc2a3 andSod2)exhibited a
statistically significant change with P,0.05 (Table S3). Compared
to OVX, major changes exhibited in Sham-OVX samples included
significant up-expression of Atp5a1 (FC=1.46; P=0.044) and
Prdx5 (FC=1.28; P=0.047), and significant down-expression of
Polg (FC=0.63; P=0.012) and Sod2 (FC=0.82; P=0.028). The
OVX-induced deficit inexpression of Atp5a1 wasreversed by CyP4
(FC=1.58; P=0.020; relative to OVX) and E2+CyP4 (FC=1.91;
P=0.046; relative to OVX). OVX-induced deficit in expression of
Prdx5 was reversed by E2+CyP4 only (FC=1.34; P=0.009;
relative to OVX), and exacerbated by E2+CoP4 (FC=0.76;
P=0.043; relative to OVX). Compared to OVX, E2 alone did
not induce a significant change in expression of any of these genes.
CoP4 and E2+CoP4 induced down-expression of select genes and
no up-expressed genes relative to OVX were detected (Table S3).
Hierarchal clustering diagrams illustrate the high degree of
similarities in the overall gene expression patterns among E2,
CoP4 and E2+CoP4 treatment groups, and among Sham-OVX,
CyP4 and E2+CyP4 treatment groups (Fig. 2A).
Cholesterol homeostasis and myelin metabolism. Of the
17 cholesterol homeostasis and myelin metabolism related genes
analyzed, 6 genes (Apoe, Cd81, Ctsb, Cyp27a1, Galc and Nr1h3)
exhibited a statistically significant change with P,0.05 (Table S3).
Compared to OVX, the only significant change exhibited in
Sham-OVX samples was the up-expression of Nr1h3 (FC=1.98;
P=0.031). OVX-induced deficit in the expression of Nr1h3 was
reversed by E2+CyP4 only (FC=2.07; P=0.035; relative to
OVX) (Table S3). The hierarchal clustering diagram revealed
again the overall similarities among E2, CoP4 and E2+CoP4
treatment groups, and among Sham-OVX, CyP4 and E2+CyP4
treatment groups; in particular, there was a high degree of
similarity among Sham-OVX and E2+CyP4 treatment groups
(Fig. 2B).
Insulin signaling and amyloid metabolism. Of the 29
insulin signaling and amyloid metabolism related genes analyzed,
7 genes (Apba1, Apba2, Apbb1, Bace1, Igf1, Ncstn and Psen2)
exhibited a statistically significant change with P,0.05 (Table S3).
Compared to OVX, major changes exhibited in Sham-OVX
samples included nearly significant up-expression of Igf1
Figure 2. Hierarchical cluster diagrams: (A) mitochondrial energy/redox metabolism related genes (18 genes; P,0.1); (B)
cholesterol homeostasis/myelin metabolism related genes (10 genes; P,0.1); (C) insulin signaling/amyloid metabolism related
genes (15 genes; P,0.1); (D) inflammation related genes (36 genes; P,0.1); (E) inflammation related genes (21 genes; P,0.05). Red
indicates high-expressing genes, green indicates low-expressing genes. Control Group=OVX; Group 1=Sham-OVX; Group 2=OVX+E2; Group
3=OVX+CoP4; Group 4=OVX+CyP4; Group 5=OVX+E2+CoP4; Group 6=OVX+E2+CyP4; OVX: ovariectomy; E2: 17b-estradiol; CoP4: continuous P4;
CyP4: cyclic P4.
doi:10.1371/journal.pone.0031267.g002
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(FC=0.77; P=0.033). OVX-induced deficit in expression of Igf1
was reversed by CyP4 (FC=1.83; P=0.019; relative to OVX) and
E2+CyP4 (FC=1.95; P=0.008; relative to OVX). Similarly,
OVX-induced increase in expression of Bace1 was reversed by
CyP4 (FC=0.77; P=0.031; relative to OVX) and E2+CyP4
(FC=0.57; P=0.0009; relative to OVX). In agreement with the
first two panels, the clustergram demonstrated similarities in
expression profiles among E2, CoP4 and E2+CoP4 treatment
groups, and among Sham-OVX, CyP4 and E2+CyP4 treatment
groups (Fig. 2C).
Inflammation. Of the 60 inflammation related genes
analyzed, 21 genes (Adrb1, C1qb, Casp1, Hrh2, Icam1, Il1rapl2,
Itgal, Itgam, Mapk1, Mapk14, Mapk8, Nfkb1, Nr3c1, Pla2g1b,
Pla2g2a, Plcb4, Plcg1, Plcg2, Ptafr, Tnfrsf1b and Vcam1) exhibited
a statistically significant change with P,0.05 (Table S3). In this
panel, all significant changes relative to OVX were in the direction
of down-expression, and there were no clear similarities in gene
expression profiles among groups. One interesting observation was
that CoP4 showed a particular impact on the expression of genes
within the Mapk family, with all three genes analyzed, Mapk1,
Mapk14 and Mapk8 being significantly down-regulated relative to
OVX. Consistent with the gene expression data, the clustergram
revealed a similar degree of divergence among groups, which,
nevertheless, revealed some degree of association among Sham-
OVX, CyP4 and E2+CyP4 treatment groups (Fig. 2D). This
association was further strengthened when only genes that had a
significant change with P,0.05 were included in the cluster analysis
(Fig. 2E). Moreover, the clustergrams revealed a clear similarity
between E2 and CoP4 treatment groups, and an association
between OVX and E2+CoP4 treatment groups (Fig. 2E).
Estrogen and progesterone receptors. Of the 9 estrogen
and progesterone receptor genes, only Pgr and Pgrmc1 exhibited a
statistically significant change with P,0.05 (Table S3). Compared
to OVX, Pgr was significantly down-regulated by E2 (FC=0.75;
P=0.009), CoP4 (FC=0.76; P=0.011) and E2+CoP4 (FC=0.73;
P=0.005). Pgrmc1 was significantly up-regulated by CyP4
(FC=1.26; P=0.028; relative to OVX) and E2+CyP4
(FC=1.49; P=0.037; relative to OVX) (Table S3).
Taken together, data across all five focused gene panels
consistently demonstrated similarities as well as divergences in
the overall gene expression profiles. Substantial differences were
observed between CoP4 and CyP4, particularly when co-
administered with E2. Of the 17 genes significantly regulated by
E2+CyP4, 7 were up-regulated and 10 were down-regulated
(Fig. 3). In contrast, 13 genes significantly regulated by E2+CoP4
were all down-regulation (Fig. 3). The major divergence between
E2+CoP4 and E2+CyP4 appeared to lie in their opposite effect on
select genes involved in mitochondrial energy production, redox
metabolism, cholesterol homeostasis, insulin signaling, and
progesterone receptors (Fig. 3). By comparison, these two E2+P4
schedules appeared to have a similar down-regulatory impact on
amyloid metabolism and inflammatory pathways at different
efficacy or involving different genes. Moreover, E2+CyP4 share a
large degree of overlap with Sham-OVX, with 6 genes similarly
regulated under both conditions. In contrast, no overlap between
E2+CoP4 and Sham-OVX was detected, and in fact, clustering of
genes at P,0.1 or P,0.05 revealed some degree of resemblance
between E2+CoP4 and OVX (Fig. 2 & 3).
CoP4 and CyP4 differentially regulate gene functional
profiles
To further understand the biological relevance of the gene
expression profiles, we conducted bioinformatics analyses using
IPA core application on 49 genes that exhibited significant
changes (P,0.05) to determine the molecular networks, canonical
pathways and biological processes (functions and diseases) that are
most significantly associated with these genes.
Molecular networks. The molecular network analysis
revealed how the molecules in the dataset are known to interact
with one another and additional molecules in the Ingenuity
Knowledge Base. Consistent with findings from the gene
expression analyses, E2+CoP4 and E2+CyP4 were associated with
disparate networks (Fig. 4). The primary network identified with the
most relevance to E2+CoP4, with a network score of 17, includes 7
focus molecules (Dnm1l, Galc, Hadh, Mfn1, Pdha1, Plcb4, Prdx5;
all of these genes were significantly regulated by E2+CoP4), and is
functionally connected to cellular compromise, changes in cell
morphology and neurological disease. The primary network
identified with the most relevance to E2+CyP4, with a network
score of 36, includes a different set of 13 focus molecules (Apba1,
Apbb1, Bace1, Icam1, Igf1, Mfn2, Nr1h3, Plcg2, Ppargc1b, Psen2,
Sirt1, Slc25a4, Slc2a3; all of these genes were significantly regulated
by E2+CyP4), and is functionally linked to gene expression, genetic
disorder and also neurological disease (Fig. 4).
Mapping of the primary networks associated with E2+CoP4 and
E2+CyP4 with the expression data from the other five treatment
groups revealed again the clear differences between E2+CoP4 and
the other groups, in particular, E2+CyP4 (Fig. 5 & 6). Within the
E2+CoP4-related primary network, Prdx5 appears the most
significant molecule that differentiates E2+CoP4 from the
remaining groups (Fig. 5). Other less significant differentiating
molecules include Galc and Hadh (Fig. 5). Within the E2+CyP4-
related primary network, Igf1 appears to act as a central node that
differentiates E2+CoP4 from the remaining groups (Fig. 6). Other
differentiators include Nr1h3, Slc25a4 and Sirt1 (Fig. 6). Mole-
cules associated with amyloid metabolism including Apba1,
Apbb1, Bace1 and Psen2, were similarly regulated by all 6 groups;
Bace1 exhibited a statistically significant down-expression relative
to OVX in response to Sham-OVX, CyP4 and E2+Cy4 (Fig. 6).
Canonical pathways. The canonical pathway analysis
identified well-characterized cell signaling and metabolic
pathways most relevant to the dataset. The top five most
significant pathways associated with E2+CoP4 include (in order
of statistical significance): LXR/RXR activation, IL-8 signaling,
lymphotoxin b receptor signaling, glucocorticoid receptor
signaling, and butanoate metabolism. The top five pathways
associated with E2+CyP4 include (in order of statistical
significance): mitochondrial function, amyloid processing, growth
hormone signaling, TREM1 signaling, and glioma signaling.
Mapping of the E2+CyP4-related mitochondrial pathway with the
expression data from all six treatment groups reveals similar
patterns to those suggested by networks. Four molecules from the
gene expression dataset are included in the pathway, with Atp5a1
identified as a member of the Complex V signaling pathway,
Bace1 and Psen2 as members of the APP signaling pathway, and
Prdx5 as a member of the redox signaling pathway (Fig. 7). The
mitochondrial energy and redox metabolism related genes, Atp5a1
and Prdx5, appear to be the key differentiators. In particular,
Sham-OVX and E2+CyP4 significantly increased, whereas
E2+CoP4 suppressed, Atp5a1 and Prdx5, compared to OVX.
The other two amyloid metabolism-related genes, Bace1 and
Psen2, were similarly down-expressed across all 6 groups relative
to OVX. For clarity of display, only a comparison between
E2+CoP4 and E2+CyP4 groupsis presented (Fig. 7).
Functions and diseases. The functional analysis enabled
association of the dataset with three primary categories of biological
functions: molecular and cellular functions, physiological system
Progesterone in Hippocampus
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with the network and pathway profiles, E2+CoP4 and E2+CyP4
were linked to different biological functions at both functional sub-
categories and specific molecules involved (Table 1). At the
molecular and cellular level, the top two functions associated with
E2+CoP4 include cellular assembly and organization, and cell
morphology. In contrast, for E2+CyP4, the top two molecular and
cellular functions are gene expression and cell survival (Table 1). At
the physiological system level, both E2+CoP4 and E2+CyP4 are
associated withnervoussystemdevelopmentand function;however,
the specific molecules involved differ. E2+CoP4 shows a greater
relevanceto tissuedevelopment, whereasE2+CyP4 is more relevant
to behavior such as learning and memory (Table 1). At the diseases
and disorders level, while both E2+CoP4 and E2+CyP4 are highly
associated with neurological disease such as dementia and more
specifically Alzheimer’s disease, distinct processes and molecules are
Figure 3. Gene expression profile associated with OVX+E2+CoP4 versus OVX+E2+CyP4 treatment paradigms. (A) Genes significantly
regulated by OVX+E2+CoP4 (17 genes; P,0.05) and/or OVX+E2+CyP4 (13 genes; P,0.05); red indicates up-regulated genes, green indicates down-
regulated genes. (B) Hierarchical cluster diagrams: mitochondrial energy/redox metabolism related genes (top panel; 12 genes; P,0.05); insulin
signaling/amyloid metabolism related genes (lower panel; 5 genes; P,0.05). Control Group=OVX; Group 1=Sham-OVX; Group 5=OVX+E2+CoP4;
Group 6=OVX+E2+CyP4. OVX: ovariectomy; E2: 17b-estradiol; CoP4: continuous P4; CyP4: cyclic P4.
doi:10.1371/journal.pone.0031267.g003
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related to cholesterol metabolism and myelin generation (Apoe,
Ctsb, Galc, Hadh), inflammation (Nfkb1, Plcb4, Vcam1), and
Pgr. Whereas E2+CyP4 is linked to processes related to
mitochondrial energy and redox metabolism (Atp5a1, Mfn2,
Polg, Ppargc1b, Sirt1, Slc25a4, Slc2a3), insulin signaling and
amyloid metabolism (Apba1, Apbb1, Bace1, Igf1, Psen2), and
Pgrmc1 (Table 1).
Figure 4. Primary molecular networks associated with OVX+E2+CoP4 versus OVX+E2+CyP4 treatment paradigms. Molecules in the
network are displayed as various shapes, which indicate the molecular class. Focus molecules (colored molecules) refer to genes from the dataset that
were significantly up- or down-regulated by a given treatment (OVX+E2+CoP4 or OVX+E2+CyP4); red indicates up-regulated genes (P,0.05), green
indicates down-regulated genes (P,0.05), gray indicates insignificantly changed genes from the dataset (P.0.05), and white indicates molecules
added from the Ingenuity Knowledge Base; color intensity indicates the degree of up or down-regulation. Lines connecting molecules indicate
molecular relationships; solid lines indicate direct interaction, dashed lines indicate indirect interactions; the type of arrows indicate specific molecular
relationships and the directionality of the interaction. OVX: ovariectomy; E2: 17b-estradiol; CoP4: continuous P4; CyP4: cyclic P4.
doi:10.1371/journal.pone.0031267.g004
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Using qRT-PCR-based Taqman low-density gene arrays and
IPA-based bioinformatics, we investigated the bioenergetics,
metabolism and inflammation-related genomic and associated
functional impact of ovarian hormonal depletion induced by OVX
and exposure to E2/CoP4/CyP4 in the adult female rat
hippocampus. Compared to Sham-OVX, OVX induced a
number of significant gene expression changes, which were to a
large extent reversed by co-administration of E2 and cyclic P4
(E2+CyP4). Co-administration of E2 and continuous P4
(E2+CoP4) induced a markedly disparate profile from that
induced by E2+CyP4; the E2+CoP4 gene expression profile
exhibited some degree of resemblance to the OVX profile.
OVX-induced changes differentiating E2+CoP4 and E2+CyP4
included genes involved in mitochondrial energy and redox
metabolism, with major genes including Atp5a1 and Prdx5,
respectively. Atp5a1 encodes the a subunit of mitochondrial ATP
synthase catalyzing ADP to ATP production [18]. ATP synthase,
the complex V which is the last complex of the mitochondrial
respiratory chain, plays a central role in synthesis of the majority of
ATP demanded in aerobic organs, particularly in metabolically
active organs such as brain [19]. Regulation of ATP synthase is
involved in physiological processes underlying normal nervous
system functions, as well as neurodegenerative processes/diseases
such as AD [20,21]. In a recent study, APP and Ab bound to ATP
synthase a subunit and regulated its activity at the surface of
neural cells, suggesting a novel mechanism in Ab-mediated AD
pathology [22]. The ATP synthase a subunit also is particularly
vulnerable to oxidative damage compared to other components of
the mitochondrial respiratory chain at earlier AD stages,
suggesting that the oxidation of ATP synthase and alterations of
its biological functions may be an early and essential step in the
pathogenesis of AD [23].
Peroxiredoxins (Prxs) are a family of thiol-dependent
antioxidant enzymes that catalyze the reduction of peroxides
[24,25]. Different from conventional antioxidants, Prxs exhibit
unique properties including high enzymatic activity through
utilization of cysteine at their active site and high cellular
abundance and involvement in both antioxidant defense and
redox signaling [24,25]. Six Prx isozymes have been identified
in mammalian cells sharing a common peroxide-scavenging
activity despite differences in their cellular distribution and
subcellular localization. Prx1 and Prx6 are expressed in
astrocytes and glial cells; Prx2, Prx3, Prx4, and Prx5 (encoded
by Prdx5) are expressed in neurons [26]. Subcellularly, Prx1,
Prx2 and Prx6 are mainly localized in the cytoplasm, Prx4 in
the endoplasmic reticulum, Prx3 in the mitochondria; Prx5 is
expressed in various compartments including peroxisomes and
mitochondria [26]. Since mitochondria are a major site of
generation of and target for hydrogen peroxide, the mitochon-
drial Prxs, including Prx3 and Prx5, play an important role in
regulation of mitochondrial redox homoeostasis [27]. Prx5 in
particular may present broader activity than other antioxidant
mitochondrial enzymes [28,29]. Overexpression of Prx5 has a
positive impact on neuronal survival and extension of lifespan;
Prx5 deficiency produces signs of oxidative stress, apoptosis, and
shortened lifespan [26,27].
Our findings of deficits in the expression of genes involved in
mitochondrial energy and redox metabolism in the hippocampus
of OVX rat brain are consistent with our previous observations
indicating vulnerability of CNS bioenergetic processes to female
endocrine aging. For instance, in female mice, we discovered a
close link between reproductive senescence and neuronal bioen-
ergetic deficit demonstrated by a significant decline in complex IV
cytochrome c oxidase activity and mitochondrial respiration [30].
The vulnerability of neuronal bioenergetics appeared to be more
prominent in AD brain, indicated by our finding in 3xTg-AD mice
that mitochondrial bioenergetic deficits in the brain preceded the
development of AD pathology [16]. Results from the present study
emphasize compromised mitochondrial energy and redox metab-
olism with ovarian disruption and are consistent with earlier
reports of age and AD related deficits in bioenergetics
[14,15,17,31]. A regimen of E2 combined with a cyclic, not
continuous, P4, could be an effective strategy for rescuing brain
from hormonal deficiency-related brain hypometabolism and
increased oxidative stress.
Another major change induced by OVX and differentially
regulated by E2+CoP4 and E2+CyP4 was in expression of Igf1.
On bioinformatics analysis, Igf1 appeared to act as a hub in the
most significant network associated with E2+CyP4. Igf1 encodes
the insulin-like growth factor I (Igf-I) that serves as a master
regulator of a wide spectrum of biological functions and
homeostasis in multiple tissues [32]. Igf-I plays an essential role
in the modulation of neural activities from early development to
adult neurogenesis, to cognition, and to protection against
neurodegenerative diseases [33]. Igf-I modulates brain levels of
Ab via regulation of proteins involved in major pathways leading
to catabolic removal of Ab [34,35,36]. Igf-I is also regulated by a
number of other factors, including the sex steroids E2 and P4.
Substantial evidence indicates crosstalk between E2 and Igf-I
signaling pathways to regulate multiple neural responses including
cognition [37,38]. Relative to E2, the impact of P4 on the Igf-I
system has been less explored. A recent report suggests that P4
may positively regulate the Igf-I system in glial cells, which could
be directly linked to a P4-mediated protection against demyelin-
ation [39]. Data from the present study supports the close
interactions between Igf-I and E2/P4; Igf-I deficit associated with
hormonal deficiency could be effectively reversed by chronic
exposure to E2+CyP4.
Additional changes induced by OVX and differentially
regulated by E2+CoP4 and E2+CyP4 included genes involved in
cholesterol homeostasis and APP intramembranous processing,
major players including Nr1h3 and Bace 1 respectively. Nr1h3
encodes the a subtype of the liver X receptor (Lxra), which, along
with Lxrb (Nr1h2), are oxysterol receptors that function as master
transcription factors mediating cholesterol homeostasis in the
periphery [40]. In the brain, emerging evidence indicates that, in
addition to the regulation of cholesterol transport and metabolism,
activation of Lxrs also attenuates inflammatory responses and Ab
production, supporting their therapeutic potential in AD man-
agement and other neurological disorders involving dysregulation
of cholesterol homeostasis [41]. Bace1 encodes b-secretase, the b-
site APP-cleaving enzyme I. [42]. Since Bace1 cleavage of APP is a
pre-requisite for Ab generation, and the level and activity of Bace1
are elevated in AD, Bace1 has been suggested as a biological
Figure 5. Mapping of the primary molecular network associated with OVX+E2+CoP4 with other hormone interventions and
treatment paradigms. Refer to Figure 4 for the network representation, except: red indicates up-regulated genes, green indicates down-regulated
genes; genes that exhibited significant changes are indicated: * P,0.05, ** P,0.01 and *** P,0.001. OVX: ovariectomy; E2: 17b-estradiol; CoP4:
continuous P4; CyP4: cyclic P4.
doi:10.1371/journal.pone.0031267.g005
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present study suggest that loss of ovarian hormones may increase
risk for the development of AD through deficits in cholesterol and
APP metabolism, which may be prevented by chronic exposure to
E2+CyP4. Compared to pathways discussed above that were
regulated in different direction by E2+CoP4 versus E2+CyP4, the
APP processing pathway appeared to be a less dramatic
differentiator since the key genes (Bace1, Psenen) involved in the
pathway were repressed by both E2+CoP4 and E2+CyP4.
The disparity between E2+CoP4 and E2+CyP4 was also
reflected on their differential regulation of P4 receptors, Pgr
versus Pgrmc1. Pgr is the classical nuclear PR and has been
associated with many neural responses to P4 [3]. In contrast to
most reports utilizing acute HT, we found that chronic HT
treatment paradigms used in the present study including E2, CoP4
and E2+CoP4 decreased Pgr. In chick embryos, acute P4 exposure
increased Pgr in hypothalamus and posterior pituitary [44]. In
adult OVX rats, E2 and combined E2 and P4 increased Pgr in
several hypothalamic nuclei, while P4 alone was not different from
OVX [45]. Although some studies document that P4 can
antagonize E2-mediated upregulation of Pgr [46], others did not
find P4 antagonism of E2 induction of Pgr [45,47]. Recent data
from our group indicate regional differences in Pgr regulation by
E2 and P4 within the adult rat hippocampus [48]. Moreover, in
the hypothalamus, OVX decreased Pgr by 80% in the medial
preoptic nucleus but by only 20% in the ventromedial nucleus
[49]. We know of only one other report of Pgr response to chronic
hormone exposure [50]. Continuous E2 treatment for 8 weeks in
OVX rats did not increase Pgr in the hypothalamus and
hippocampus [50]. Together, these data suggests that Pgr
regulation by E2 and P4 could be highly dependent upon the
duration of hormone treatment, as well as brain region.
In contrast to Pgr, Pgrmc1 is a membrane-associated PR and a
member of a multi-protein complex regulating a spectrum of
hormone-signaling pathways [51]. Pgrmc1 is expressed in multiple
brain regions, mediates P4-induced responses in multiple neural
cell types, and is suggested to play a role in the promotion of
neonatal dendritic growth, spino- and synapto-genesis [52,53,54].
Further, our previous analysis revealed that Pgrmc1 mediated P4-
induced increase in cell cycle gene expression and proliferation in
rat neural progenitor cells [55]. The present study demonstrated
that CyP4 alone or with E2 induced an up-regulation of Pgrmc1.
E2 and CyP4 interacted synergistically since the response to
E2+CyP4 was greater than the response induced by CyP4 alone.
In contrast, an antagonistic interaction occurred between E2 and
CoP4 where Pgrmc1 expression decreased. Together, these results
Figure 6. Mapping of the primary molecular network associated with OVX+E2+CyP4 with other hormone interventions and
treatment paradigms. Refer to Figure 4 for the network representation, except: red indicates up-regulated genes, green indicates down-regulated
genes; genes that exhibited significant changes are indicated: * P,0.05, ** P,0.01 and *** P,0.001. OVX: ovariectomy; E2: 17b-estradiol; CoP4:
continuous P4; CyP4: cyclic P4.
doi:10.1371/journal.pone.0031267.g006
Figure 7. Differential impact on mitochondrial functional pathway by different hormone interventions and treatment paradigms.
Molecules in the pathway are displayed as various shapes, which indicate the molecular class (refer to Figure 4). Colored molecules refer to genes
from the dataset; red indicates up-regulated genes, green indicates down-regulated genes; genes that exhibited significant changes are indicated:
*P ,0.05, ** P,0.01 and *** P,0.001. OVX: ovariectomy; E2: 17b-estradiol; CoP4: continuous P4; CyP4: cyclic P4.
doi:10.1371/journal.pone.0031267.g007
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patterns between E2+CoP4 and E2+CyP4 could be closely
associated with their differential regulation of Pgrmc1.
It should be pointed out that, technically and statistically, this
study presents both strengths and limitations. One issue arisen was
the consideration of adjustment for multiple hypothesis testing: an
approach such as consideration of the false positive discovery rate,
in particular, is usually required in microarray studies where
thousands of genes are analyzed simultaneously. Because of the
relatively large chance for false positive discoveries involved in
such high density microarray studies, findings usually need to be
further validated by real-time RT-PCR analysis. In our study, we
directly used the real-time RT-PCR technique following a
carefully developed and validated protocol, and as part of this
protocol, our low-density array consisting of a pathway-focused set
of target genes was custom designed based on prior literature and
hypothesized associations with neurological aging dysfunctions as
well as hormone therapy interventions. Therefore, in consider-
ation of three factors: 1) the well-designed and quality-controlled
technical strengths, 2) the intent to reduce false negatives in this
first-ever analysis, 3) the by and large internal agreement of our
findings with published functional data, we did not control for
multiple hypothesis testing, and instead, chose to present
unadjusted p-values in this study. Given these reasons, we however
recognize the possibility of false positive associations and the need
for independent validation in larger studies.
Collectively, our findings from the present study demonstrate
that, consistent with many preclinical and clinical observations,
surgically-induced ovarian hormone loss exerts a negative impact
on multiple biological processes in the brain, including mitochon-
Table 1. Top functions/diseases associated with OVX+E2+CoP4 versus OVX+E2+CyP4 treatment paradigm.
Functional Category OVX+E2+CoP4 OVX+E2+CyP4
Molecular and Cellular Function Cellular Assembly and Organization
N 7 molecules: Apoe, Ctsb, Dnm1l, Mfn1, Nfkb1, Pgr, Vcam1
N P-value range: 1.34E-06–8.70E-03
N Relevant functions include (in the order of statistical
significance): density; distribution; quantity; morphology;
formation; nucleation; disruption; export; interconnectivity;
rearrangement; tubulation; outgrowth; accumulation;
leakage; volume; fusion; reorganization; biogenesis;
localization; proliferation; aggregation
Gene Expression
N 7 molecules: Apba1, Apba2, Igf1, Nr1h3, Polg,
Ppargc1b, Sirt1
N P-value=3.68E-06–6.83E-03
N Relevant functions include (in the order of statistical
significance): co-activation; activation; transactivation;
transcription; binding
Cell Morphology
N 7 molecules: Apoe, Dnm1l, Itgam, Mfn1, Nfkb1, Pgr, Vcam1
N P-value=2.11E-06–9.00E-03
N Relevant functions include (in the order of statistical
significance): length; cell spreading; morphology; shape
change; cellularity; innervation; tubulation; outgrowth;
volume; frequency; size
Cell Survival
N 12 molecules: Apbb1, Bace1, Icam1, Igf1, Mfn2,
Nr1h3, Plcg2, Prdx5, Psen2, Sirt1, Slc25a4, Slc2a3
N P-value=5.61E-06–6.65E-03
N Relevant functions include (in the order of statistical
significance): cell death; apoptosis; survival; loss;
necrosis; regeneration; cytotoxicity; activation-induced
cell death; anoikis; cell viability
Physiological System Development
and Function
Nervous System Development and Function
N 8 molecules: Apoe, Dnm1l, Itgam, Mfn1, Nfkb1,
Plcb4, Pgr, Vcam1
N P-value=1.34E-05–8.70E-03
N Relevant functions include (in the order of
statistical significance): density; cell viability; distribution;
morphology; innervation; quantity; outgrowth;
differentiation; long-term depression; long-term
memory; length
Nervous System Development and Function
N 8 molecules: Apbb1, Bace1, Icam1, Igf1, Mfn2,
Nr1h3, Psen2, Sirt1
N P-value=4.40E-05–5.70E-03
N Relevant functions include (in the order of statistical
significance): Neurogenesis; proliferation; memory;
survival; density; formation; spatial learning; spatial
memory; neurological process; neuroprotection; cell
movement; growth; quantity; size; stimulation;
vascularization; accumulation; activation; branching;
height; inhibition; shrinkage; stabilization; volume;
area; morphology; myelination; plasticity;
regeneration; innervation
Tissue Development
N 5 molecules: Apoe, Itgam, Nfkb1, Pgr, Vcam1
N P-value=7.03E-06–8.70E-03
N Relevant functions include (in the order of statistical
significance): adhesion; accumulation; development;
branching; binding; formation; generation; adherence;
cell-cell contact; growth; aggregation
Behavior
N 6 molecules: Apba1, Apbb1, Bace1, Igf1, Ppargc1b,
Psen2
N P-value=1.67E-05–4.56E-03
N Relevant functions include (in the order of statistical
significance): learning; spatial learning; hyperactivity;
memory; spatial memory; anxiety; mating behavior;
locomotion
Diseases Neurological Disease
N 11 molecules: Apoe, Ctsb, Dnm1l, Galc, Hadh,
Mfn1, Nfkb1, Pdha1, Pgr, Plcb4, Vcam1
N P-value=4.07E-05–6.97E-03
N Relevant diseases include (in the order of statistical
significance): neurological disorder; neurodegenerative
disorder; dementia; astrocytosis; cerebrotendinous
xanthomatosis; microgliosis; Alzheimer’s disease;
disaggregation; age-related hearing loss; atrophy;
enlargement; Krabbe’s disease; stroke; organismal
abnormalities; tumorigenesis
Neurological Disease
N 15 molecules: Apba1, Apbb1, Atp5a1, Bace1, Icam1,
Igf1, Mfn2, Pgrmc1, Plcg2, Polg, Ppargc1b, Psen2, Sirt1,
Slc25a4, Slc2a3
N P-value=2.89E-08–4.56E-03
N Relevant diseases include (in the order of statistical
significance): dementia; Alzheimer’s disease;
neurological disorder; familial Alzheimer’s disease;
retinopathy; gliosis; infarction; Charcot-Marie-Tooth
disease type 2A1; amyotrophic lateral sclerosis
doi:10.1371/journal.pone.0031267.t001
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cholesterol trafficking, insulin signaling and amyloid metabolism,
all of which, as discussed above, play a critical role in neurological
health and disease. Further, data contained herein indicate that
systems of gene expression in brain are differentially impacted by
exposure to cyclic versus continuous hormone interventions and
treatment paradigms. A regimen of E2 combined with a cyclic
exposure to P4, which more closely mimics the natural female
hormone pattern, induced gene expression profiles consistent with
the ovary intact brain. In stark contrast, a regimen of E2 combined
with a continuous combined exposure to P4, which more closely
mimics the clinical hormone therapy regimen, induced gene
expression profiles consistent with the ovarian hormone deficient
brain. These preclinical data require confirmation in a model of
natural menopause but suggest that a hormone therapy of E2 and
cyclic exposure to P4 would be a promising therapeutic strategy
for preventing or reducing hormonal deficiency-induced compro-
mise on neurological health and function.
Materials and Methods
Chemicals
E2/P4 and corresponding placebo pellets manufactured for
long term continuous release were purchased from Innovative
Research of America (Sarasota, FL).
Animals and treatment
The use of animals and treatment were approved by the
Institutional Animal Care and Use Committee at the University of
Southern California (Protocol No. 10911). Three-month-old
Sprague-Dawley female rats were ovariectomized (OVX) at
Harlan (Indianapolis, IN). Animals were randomized into 7
treatment groups (N=8/group): Sham-OVX (treated with vehicle
only), OVX (treated with vehicle only), OVX+E2, OVX+CoP4,
OVX+CyP4, OVX+E2+CoP4, OVX+E2+CyP4 (Fig. 1A). For E2
(treated with the 190 mg/60 d pellets) and CoP4 (treated with the
450 mg/60 d pellets) exposure, pellets were subcutaneously
implanted on day_7 after OVX and remained for the entire
60_day experiment. For CyP4 (treated with the 50 mg/10 d
pellets) exposure, pellets were subcutaneously inserted on day_20
and day_50 after E2 treatment (day_27 and day_50 after OVX).
Animals were killed by perfusion on day_60 after initiation of E2/
P4 treatment (day_67 after OVX) (Fig. 1A). The uterus was
collected and the uterine weight was used to confirm hormone
treatments (Fig. 1B). Brain hemispheres were dissected and frozen.
Hippocampal tissues yielded from 4 animals per group were used
for gene expression profiling analysis (tissues from the other 4
animals were used for protein and other biochemical analyses).
TLDA gene expression profiling
Taqman low-density array (TLDA) technology, based upon the
quantitative RT-PCR platform, has recently emerged as a novel
tool for gene expression profiling, providing a focused, sensitive,
reproducible and medium-high throughput approach to simulta-
neously measure expression of up to 384 genes in single samples
[56].
In the present study, TLDA cards (Format 48, which enables
analysis of 4 samples in duplicate against 48 different genes) were
custom manufactured at Applied Biosystems (Foster City, CA),
and loaded with Taqman expression assays for target genes
divided into five functional groups and 4 assays for candidate
control genes (Table S1). Total RNA was isolated from rat
hippocampal tissues using the PureLink RNA Mini Kit (Invitro-
gen, Carlsbad, CA). RNA quantity and quality were analyzed
using the Experion RNA StdSens Analysis Kit on an Experion
Automated Electrophoresis System (Bio-Rad, Hercules, CA). The
integrity of RNA samples was assessed by the Relative Quality
Indicator (RQI, scale 1–10 colored from red to orange to green)
[57]. RNA samples with the RQI reading greater than 8.0 were
advanced to cDNA synthesis. RNA to cDNA synthesis was
prepared using the High Capacity RNA-to-cDNA Master Mix
(Applied Biosystems) on a MyCycler Thermal Cycler (Bio-Rad).
Taqman real-time qRT-PCR reactions were performed on 50 ng
cDNA samples mixed with the TaqMan Universal PCR Master
Mix 26 (Applied Biosystems), under the thermal cycling
conditions: stage 1: AmpErase UNG activation at 50uC/2 min/
100% ramp; stage 2: AmpliTaq gold DNA polymerase activation
at 94.5uC/10 min/100% ramp; stage 3: melt at 97uC/30 sec/
50% ramp, followed by anneal/extend at 59.7uC/1 min/100%
ramp, for 40 cycles. Fluorescence was detected on an ABI
7900HT Fast Real-Time PCR System equipped with the
Sequence Detection System Software Version 2.3 (Applied
Biosystems).
Data were analyzed using the RQ Manager Version 1.2 and
DataAssist Version 2.0 (Applied Biosystems). Relative gene
expression levels or fold changes relative to the comparison group
(OVX treated with vehicle only) were calculated by the
comparative Ct (DDCt) method, with Ct denoting threshold cycle
[58]. Selection of the endogenous control gene for normalization
was based on the control stability measure (M), which indicates the
expression stability of control genes on the basis of non-normalized
expression levels. M was calculated using the geNorm algorithm;
genes with the lowest M values have the most stable expression.
Four samples (collected from 4 animals) per group were included
in the analysis. For each sample, average Ct for each target gene
was calculated as the mean of 2 technical replicates; DCt was
calculated as the difference in average Ct of the target gene and
the endogenous control gene. For each treatment group, mean
2
2DCt was calculated as the geometric mean of 2
2DCt of the 4
samples in the group. Fold change was then calculated as mean
2
2DCt (treatment group)/mean 2
2DCt (comparison group). Fold change
values greater than one indicate a positive expression or up-
regulation relative to the comparison group. Fold change values
less than one indicate a negative expression or down-regulation
relative to the comparison group. Fold regulation was used to
represent the fold change results in a biologically meaningful way.
For fold change values greater than one (up-regulation), the fold
regulation is equal to the fold change; for fold change values less
than one (down-regulation), the fold regulation is the negative
inverse of the fold change. The 2
2DCt values for each target gene
were statistically compared between the treatment and comparison
group using Student’s t-test. As a result, a total of 139 target genes
were analyzed for expression changes between 6 treatment groups
and the OVX control group, which yielded a total of 13966=834
statistical tests. The statistical significance was indicated by
*P ,0.05, ** P,0.01 and *** P,0.001; P-values were unadjusted
by multiple testing corrections, a statistical method to correct for
occurrence of false positive discoveries (an explanation is included
in Discussion).
Hierarchical clustering diagrams graphically displayed clusters
of treatment groups as well as target genes. Distances between
treatment groups/target genes, shown in maximum linkage, were
calculated by clustering algorithm Pearson’s correlations based on
the DCt values.
IPA gene functional profiling
IPA (Ingenuity Systems, Redwood City, CA), which leverages
the Ingenuity Knowledge Base, the largest database housing
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literature, provided a bioinformatics computing tool to interpret
our experimental gene expression dataset in the context of
biological processes, pathways, and molecular networks (www.
ingenuity.com). Data including only statistically significantly
altered genes (P,0.05) containing gene identifiers and corre-
sponding fold regulation values was uploaded into IPA 8.7 and
analyzed by a core analysis composed of a network analysis, a
canonical pathway analysis and a function/disease analysis.
The network analysis identified biological connectivity among
molecules in the dataset that were significantly up- or down-
regulated by a given treatment (these molecules are called
‘‘network eligible molecules’’ or ‘‘focus molecules’’ that serve as
‘‘seeds’’ for generating networks) and their interactions with other
molecules present in the Ingenuity Knowledge Base. Network
eligible molecules were combined into networks that maximized
their specific connectivity. Additional molecules from the Ingenu-
ity Knowledge Base (these molecules are called ‘‘interacting
molecules’’) were used to specifically connect two or more smaller
networks to merge them into a larger one. A network was
composed of direct (requiring direct physical contact between two
molecules) and indirect (mediated by intermediate factor(s))
interactions among focus molecules and interacting molecules,
with a maximum of 35 molecules per network. Generated
networks were ranked by the network score according to their
degree of relevance to the network eligible molecules from the
dataset. The network score was calculated with Fisher’s exact test,
taking into account the number of network eligible molecules in
the network and the size of the network, as well as the total
number of network eligible molecules analyzed and the total
number of molecules in the Ingenuity Knowledge Base that were
included in the network. Higher network scores are associated with
lower probability of finding the observed number of network
eligible molecules in a given network by chance.
The canonical pathway analysis identified the cell signaling and
metabolic pathways stored in the Ingenuity Knowledge Base that
were most significant to the dataset. The significance of the
association between the dataset and a given canonical pathway
was measured in two ways: 1) a ratio of the number of molecules
from the dataset that map to the pathway divided by the total
number of molecules that are contained in that pathway, and 2) a
P-value calculated by Fisher’s exact test. P-values less than 0.05
indicate a statistically significant, non-random association between
a set of molecules in the dataset and a given canonical pathway.
The functional analysis identified the biological functions and
diseases that were most significant to the dataset. Fisher’s exact test
was used to calculate the P-value, considering 1) the number of
molecules in the dataset that participate in that function/disease,
and 2) the total number of molecules that are known to be
associated with that function/disease in the Ingenuity Knowledge
Base. P-values less than 0.05 indicate a statistically significant, non-
random association between a set of molecules in the dataset and a
given function/disease.
We used the IPA network/pathway to graphically depict the
biological relationships between molecules. Molecules are present-
ed as nodes, and the biological relationship between two modes is
represented as an edge (line). All edges are supported by at least
one reference from the literature, from a textbook, or from
canonical information stored in the Ingenuity Knowledge Base.
The intensity of the node color indicates the degree of up- (red) or
down- (green) regulation relative to the comparison group. Nodes
are displayed using various shapes that represent the functional
class of the gene product. Edges are displayed with various labels
that describe the nature of the relationship between the nodes.
Solid lines indicate direct relationships, dashed lines indicate
indirect relationships, and circular arrows or lines indicate self-
referential relationships that arise from the ability of a molecule to
act upon itself.
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